Molecule: Purified thymic peptide complex (standardized extract of low-molecular weight thymic peptides: thymulin, thymosin α1-like fragments, prothymosin-related peptides)
Classification: Thymic immunomodulator • Pro-regenerative peptide complex • Endogenous immunity-restoration agent
Originally developed in the former USSR. Supports T-cell differentiation, immune homeostasis, cytokine regulation, anti-inflammatory balance, protein synthesis, DNA/RNA repair, and health-span optimization. Used to normalize impaired immune responses, improve stress-weakened immunity, and support healthy immune aging.
Increases CD3+, CD4+, CD8+ T-cell subsets. Regulates T-helper/T-suppressor balance. Enhances antigen-specific response. Restores thymic-like endocrine function. Stronger, more balanced cellular immunity in suppressed/dysregulated states.
Reduces IL-6, IL-1β, TNF-α. Increases IL-2 and interferon responsiveness. Normalizes inflammatory cascades. Better immune stressor tolerance.
Increased bone-marrow myelopoiesis. Improved neutrophil/lymphocyte recovery. Enhanced resilience after chemotherapy, radiation, infection.
Protein synthesis, DNA/RNA repair, fibroblast/endothelial renewal, reduced inflammaging markers. Improved immune age profile and systemic rejuvenation.
Reduces excessive inflammation, tissue damage from immune overactivation, fibrosis in stressed tissues. Supports post-illness/injury/surgery recovery.
Immune suppression (stress, chronic illness), recurrent infections, post-viral dysfunction, age-related decline, chemotherapy-associated depletion.
Russian longevity studies: reduced mortality markers, improved immune profiles, reduced inflammatory cytokines, better functional aging.
Acute respiratory infections, severe influenza recovery, post-viral fatigue, convalescence after major illness.
Faster epithelial repair, lower inflammation, enhanced fibroblast activity.
Overtraining (athletes), shift workers, chronic stress/burnout, high allostatic load patients.
10 mg vial: 2 mL bacteriostatic saline → 5 mg/mL, or 4 mL → 2.5 mg/mL.
Acute: 5–14 days. Maintenance: 6–12 weeks intermittent. Longevity: quarterly or biannual cycles.
Immune suppression? → YES
Chronic inflammation / inflammaging? → YES
Frequent infections? → YES
Recent viral illness / recovery? → YES
Improved tissue healing? → YES
Autoimmunity flare? → Case-by-case
Rapid immune boost → 10 mg daily × 5–10 days
Longevity → 5 mg daily × 10 days, quarterly
Post-illness → 10 mg daily × 7 days → taper
Athlete stress → 5 mg SC 2–3×/wk
Extremely well tolerated. Possible: mild injection-site redness, temporary fatigue or energy lift, mild flu-like response 24–48 hrs (immune activation). No serious adverse events in decades of literature.
This document is provided solely for educational and informational purposes. Thymalin and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.